Friday, July 31

Browsing: sBLA

Treatments

FDA Accepts SC Mosunetuzumab Combo sBLA in Relapsed/Refractory LBCL

By NewsCancerJune 19, 20260

The FDA has accepted a supplemental biologics license application (sBLA) for a subcutaneous formulation of mosunetuzumab (Lunsumio VELO) in combination…

Diagnosis

FDA Receives sBLA for Zenocutuzumab in Advanced NRG1+ Cholangiocarcinoma

By NewsCancerApril 15, 20260

The FDA has received a supplemental Biologics License Application (sBLA) for zenocutuzumab-zbco (Bizengri) for the treatment of patients with advanced…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

Browsing: sBLA

FDA Accepts SC Mosunetuzumab Combo sBLA in Relapsed/Refractory LBCL

FDA Receives sBLA for Zenocutuzumab in Advanced NRG1+ Cholangiocarcinoma

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

Latest Post

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

Subscribe to Updates

What's Hot

Browsing: sBLA